Shilpa Medicare Ltd

Shilpa Medicare Ltd | Sector: Pharmaceuticals | ISIN: INE790G01031

₹ 240.95 (-0.29%) icon

24 Mar, 2023, 3:50:41 PM
Open
₹ 242.90
Prev. Close
₹ 241.65
Turnover(lac)
₹ 5,319.63
Day's High
₹ 255.00
Day's Low
₹ 238.20
52 Wk High
₹ 503.00
52 Wk Low
₹ 231.00
Book Value
₹ 247.90
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 2,091.49
P/E
134.22
EPS
1.80
Div. Yield
0.46

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/24/2023 3:50:41 PM

    ₹ 240.95 -0.70 -0.29
  • Open
  • ₹ 242.9
  • Prev. Close
  • ₹ 241.65
  • Turnover(Lac.)
  • ₹ 5,320
  • Day's High
  • ₹ 255
  • Day's Low
  • ₹ 238.2
  • 52 Week's High
  • ₹ 503
  • 52 Week's Low
  • ₹ 231
  • Book Value
  • ₹ 247.9
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 2,091.49
  • P/E
  • 134.22
  • EPS
  • 1.8
  • Divi. Yield
  • 0.46

Corporate Actions

03 Feb , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Feb , 2023

12:00 AM

03 Nov , 2022

12:00 AM

03 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 Aug , 2022

12:00 AM

AGM

Announcement date: 19 Aug , 2022

View Details

23 May , 2022

12:00 AM

Dividend

Dividend amount: 1.1
Announcement date: 23 May , 2022

View Details

03 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Aug , 2022

12:00 AM

25 Apr , 2022

12:00 AM

16 May , 2022

12:00 AM

16 May , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

16 Aug , 2022

12:00 AM

BookCloser

View Details

SHAREHOLDING SNAPSHOT
27 March , 2023 | 12:49 AM

PROMOTER - TOTAL50.01%

Indian: 50.01%

Foreign: 0%

NON-PROMOTER - TOTAL 49.99%

Institutions: 15.95%

Non-Institutions: 34.04%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Shilpa Medicare Ltd News and Update

Image not found
  • 24 March, 2023 |
  • 4:03 PM

According to a BSE filing, the parties to the proposed transaction, for which a legally binding memorandum of understanding had previously been signed, had "executed a Share Purchase Agreement and finalized the transaction."

Article Image
Article Image
  • IIFL News Service |
  • 23 March, 2023 |
  • 4:02 PM
ad IconAd Image

FINANCIALS

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Shilpa Medicare Ltd

  • Omprakash Inani

  • Chairman (Non-Executive)
  • Vishnukant Bhutada

  • Managing Director
  • Pramod Kasat

  • Non-Exec. & Independent Dir.
  • Rajender Sunki Reddy

  • Non-Exec. & Independent Dir.
  • Sirisha Chintapalli

  • Non-Exec. & Independent Dir.
  • Sharath Reddy Kalakota

  • Whole-time Director
  • Arvind Vasudeva

  • Independent Director
  • Hetal Gandhi

  • Independent Director
  • Ritu Tiwary

  • Company Sec. & Compli. Officer
  • Kamal K Sharma

  • Addtnl Independent Director
  • Anita Bandyopadhyay

  • Addtnl Independent Director

Summary

Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SMLs underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SMLs product range includes over 44 oncology and non-oncology APIs. The Companys formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SMLs wholly owned subsidiary Shilpa... Read More


Reports by Shilpa Medicare Ltd


Reports by Shilpa Medicare Ltd